Efficacy and cardiotoxicity of liposomal doxorubicin-based chemotherapy in advanced breast cancer: A meta-analysis of ten randomized controlled trials

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Xing, Meiyuan ^a   Yan, Feifei ^a   Yu, Sufen ^a   Shen, Peng ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ANTINEOPLASTIC AGENT; LIPOSOME; MACROGOL DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; CARDIOTOXICITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CARCINOMA; CHEMICALLY INDUCED; FEMALE; HEART DISEASE; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; PATHOLOGY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; HEART DISEASES; HUMANS; LIPOSOMES; MULTICENTER STUDIES AS TOPIC; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84941614211     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0133569     Document Type: Article

References (28)

1. Ban KA, Godellas CV. Epidemiology of breast cancer. Surg Oncol Clin N Am. 2014;23:409-422. doi: 10.1016/j.soc.2014.03.011 PMID: 24882341
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-1717. PMID: 15894097
3. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125:47-58. PMID: 8644988
4. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869-2879. PMID: 12767102
5. Bria E, Cuppone F, Fornier M, Nisticò C, Carlini P, Milella M, et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat. 2007;109:231-239. PMID: 17638068
6. Lao J, Madani J, Puértolas T, Alvarez M, Hernández A, Pazo-Cid R, et al. Liposomal doxorubicin in the treatment of breast cancer patients: a review. J Drug Deliv. 2013;2013:456409. doi: 10.1155/2013/456409 PMID: 23634302
7. Schmid P, Krocker J, Kreienberg R, Klare P, Kittel K, Sommer H, et al. Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial. Cancer Chemother Pharmacol. 2009;64:401-406. doi: 10.1007/s00280-008-0887-3 PMID: 19104816
8. Rosati MS, Raimondi C, Baciarello G, Grassi P, Giovannoni S, Petrelli E, et al. Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial (phase I-II). Ann Oncol. 2011;22:315-320. doi: 10.1093/annonc/mdq392 PMID: 20693299
9. Rochlitz C, Ruhstaller T, Lerch S, Spirig C, Huober J, Suter T, et al. Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Ann Oncol. 2011;22:80-85. doi: 10. 1093/annonc/mdq319 PMID: 20595448
10. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2011;19:1444-1454.
11. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002;94:25-36. PMID: 11815957
12. Sparano JA, Makhson AN, Semiglazov VF, Tjulandin SA, Balashova OI, Bondarenko IN, et al. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. J Clin Oncol. 2009;27:4522-4529. doi: 10.1200/JCO.2008.20.5013 PMID: 19687336
13. Chan S, Davidson N, Juozaityte E, Erdkamp F, Pluzanska A, Azarnia N, et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol. 2004;15:1527-1534. PMID: 15367414
14. Furlan AD, Pennick V, Bombardier C, Van Tulder M, Editorial Board CBRG. 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine (Phila Pa 1976) 2009;34:1929-1941.
15. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 2004;23:1817.
16. Hamaker ME, Seynaeve C, Wymenga AN, Van Tinteren H, Nortier JW, Maartense E, et al. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group. Breast. 2014;23:81-87. doi: 10.1016/j.breast.2013.11.004 PMID: 24314824
17. Yardley DA, Burris HA, Spigel DR, Clark BL, Vazquez E, Shipley D, et al. A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast cancer. Clin Breast Cancer. 2009;9:247-252. doi: 10.3816/CBC.2009.n. 042 PMID: 19933081
18. Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol. 2004;22:3893-3901. PMID: 15459210
19. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440-449. PMID: 14998846
20. Vici P, Colucci G, Giotta F, Sergi D, Filippelli G, Perri P, et al. A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. J Exp Clin Cancer Res. 2011;30:39. doi: 10. 1186/1756-9966-30-39 PMID: 21481280
21. Baselga J, Manikhas A, Cortés J, Llombart A, Roman L, Semiglazov VF, et al. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol. 2014;25:592-598. doi: 10.1093/annonc/mdt543 PMID: 24401928
22. Smorenburg CH, De Groot SM, Van Leeuwen-Stok AE, Hamaker ME, Wymenga AN, De Graaf H, et al. A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG. Ann Oncol. 2014;25:599-605. doi: 10.1093/annonc/mdt588 PMID: 24504445
23. Levine MN, Whelan T. Adjuvant chemotherapy for breast cancer-30 years later. N Engl J Med. 2006;355:1920-1922. PMID: 17079767
24. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185-229. PMID: 15169927
25. Kanter PM, Bullard GA, Pilkiewicz FG, Mayer LD, Cullis PR, Pavelic ZP. Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): comparison with doxorubicin and empty liposomes in mice and dogs. In Vivo. 1993;7:85-95. PMID: 8504212
26. Crivellari D, Gray KP, Dellapasqua S, Puglisi F, Ribi K, Price KN, et al. Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial. Breast. 2013;22:130-137. doi: 10. 1016/j.breast.2013.01.015 PMID: 23453899
27. Alba E, Ruiz-Borrego M, Martin M, Rodríguez-Lescure A, Sánchez-Rovira P, Ruiz A, et al. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Res Treat. 2010;122:169-176. doi: 10.1007/s10549-010-0860-9 PMID: 20361253
28. Verma S, Dent S, Chow BJ, Rayson D, Safra T. Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat Rev. 2008;34:391-406. doi: 10. 1016/j.ctrv. 2008.01.008 PMID: 18358614